# TARGET PharmaSolutions

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/target-pharmasolutions

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.targetrwe.com
- Total disclosed funding: $2M
- Latest round: Series A (Mar 1, 2016)
- Investors on record: 2

## About

TARGET PharmaSolutions, Inc., based in the US, excels in generating longitudinal datasets through advanced analytics, focusing on real-world evidence in healthcare for liver disease, gastroenterology, and dermatology.Founded in 2015, TARGET PharmaSolutions, Inc. operates from its headquarters in Durham, US, specializing in developing detailed disease registries. The company was established by Meg Powell and Michael Fried. In its funding journey, TARGET PharmaSolutions raised USD 2.00 mn in its SERIES A round led by Rex Health Ventures, bringing its total amount raised to USD 2.00 mn through three distinct deals. The current CEO is Derek Evans.Target RWE specializes in generating comprehensive longitudinal datasets utilizing advanced analytics and causal inference methodologies. Its core offerings revolve around the development of detailed disease registries, particularly in liver disease, gastroenterology, and dermatology. These registries amalgamate patient and clinician-reported outcomes with biosamples, providing robust insights into disease progression, treatment efficacy, and safety in real-world settings. Target RWE’s services cater to a diverse clientele, including pharmaceutical companies, healthcare providers, and regulatory agencies, primarily in the United States and Europe. The company's collaborative academic model facilitates partnerships with clinical investigators to enhance data collection and analysis, further broadening its impact in the healthcare landscape.Target RWE's revenue is derived from a combination of subscription-based models and partnerships with various stakeholders in the healthcare sector. The company engages with clients through tailored research agreements that leverage its extensive patient registries for real-world evidence generation. These transactions typically involve fees for access to proprietary analytics software, such as causalRisk™ and causalPHR™, as well as services related to regulatory compliance and pharmacovigilance. While specific pricing structures for products and services are not disclosed, the firm’s offerings are designed to meet the needs of its client base while providing comprehensive solutions for new drug applications and post-marketing commitments. Through these strategic collaborations, Target RWE capitalizes on its expertise to deliver actionable insights that inform clinical and commercial decision-making.TARGET PharmaSolutions, Inc. has plans for future growth that include the development of new products aimed at enhancing its disease registries, though specific release dates have not been disclosed. The company is also targeting geographic expansion into new markets, with a focus on increasing its presence in Europe. Recent funding from 22C Capital will be utilized to support these initiatives, enabling the company to scale its operations and broaden its impact in the healthcare sector.

## Funding rounds

- Series A, Mar 1, 2016, $2M — VentureSouth, Rex Health Ventures

## Investors

- VentureSouth (https://capitalatlas.ai/funds/venturesouth) — Series A
- Rex Health Ventures (https://capitalatlas.ai/funds/rex-health-ventures) — Series A